Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI

Similar papers

Open access Sep 2026

Biomarker-defined benefit from FLOT plus nivolumab in metastatic gastroesophageal cancer: Extended follow-up and immune-inflammatory markers of the phase II IKF-AIO-moonlight trial.

BACKGROUND First-line treatment of PD-L1-positive advanced gastroesophageal adenocarcinoma (GEA) combines doublet 5-FU/platinum with anti-PD1 inhibition. While triplet chemotherapy (FLOT/TFOX) has demonstrated efficacy alone, data on the combination of FLOT with immunotherapy remain sparse. Given the intensity of tripl...

M. Masetti, A. Nieto, Sylvie Lorenzen et al. · 0 citations
Open access Sep 2026

PD-L1 Expression as a Predictor of Response to Neoadjuvant Immunotherapy in Triple-Negative Breast Cancer

Background: Immune checkpoint blockade has changed the treatment of high-risk early-stage triple-negative breast cancer (TNBC), yet the clinical role of programmed death-ligand 1 (PD-L1) expression in the neoadjuvant setting remains unsettled. PD-L1 may identify an immune-enriched tumor microenvironment and therefore c...

Naznin Nahida, Dhruba Tasnim, Israt Jahan Mukta et al. · 0 citations
Open access Sep 2026

A multi-omics analysis of advanced triple-negative breast cancer identifies predictors to chemo-immunotherapy and on-treatment dynamics.

F fibrovascular and myeloid reprogramming is establish fibrovascular and myeloid reprogramming as a coordinated resistance program, identify actionable therapeutic targets, and support microenvironment stratification in future ICI-based trials.

N. Van Renne, E. Agostinetto, Andrea Joaquín-García et al. · 0 citations
Open access Oct 2026

Multimodal Immune Profile Score (IPS) as a Pan-Cancer Biomarker for Stratifying Outcomes of Immune Checkpoint Inhibitor Benefit in Microsatellite Stable Colorectal Cancer and Rare Solid Tumors

Background Immune checkpoint inhibitor (ICI) therapies have revolutionized oncology, but identifying patients who benefit remains a challenge, particularly in populations where ICIs are not the standard of care, including microsatellite stable colorectal cancer (MSS CRC) and rare solid cancers. We evaluated real-world...

M. Ting-Lin, E. Antonarakis, X. Wang et al. · 0 citations
Review Open access Oct 2026

PD-1/PD-L1 inhibitors combined with chemotherapy or as monotherapy versus chemotherapy alone or observation in triple-negative breast cancer: a systematic review and updated meta-analysis incorporating long-term survival data

Multiple RCTs have established PD-1/PD-L1 inhibitors as standard in triple-negative breast cancer (TNBC), but prior meta-analyses lacked complete setting coverage, mature long-term survival data, and a quantification of chemotherapy-backbone impact—critical given IMpassion130 (nab-paclitaxel, positive) vs. IMpassio...

Bing Guan, Ya-Wen Chen, Rong Zhou et al. · 0 citations
Open access Aug 2026

Integration of a severe immune-related adverse events predictive model with efficacy biomarkers enables precise stratification in NSCLC immunotherapy: insights from the phase 3 ORIENT-11 study

Severe immune-related adverse events (irAEs) compromise the outcomes of immune checkpoint inhibitors (ICIs). However, in routine practice, clinicians still lack biomarkers that can prospectively disentangle antitumor efficacy from the risk of severe irAEs, resulting in largely empirical, one-size-fits-all use of...

Yuecheng Peng, Ling Wen, Jia-Le Shen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.